Browsing by Author "Miranda, Silvana Spindola de"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Detection of drug resistant mycobacterium tuberculosis strains using Kit SIRE Nitratase® : a multicenter study.
    (2020) Miranda, Silvana Spindola de; Almeida, Isabela Neves de; Mansur, Maria de Fátima Filardi Oliveira; Figueredo, Lida Jouca de Assis; Carvalho, Wânia da Silva; Hadaad, João Paulo Amaral; Diniz, Jaciara de Lourdes do Carmo Guimarães; Groll, Andrea von; Silva, Pedro Almeida da; Lopes, Maria Luiza; Santos, Marcelo Cordeiro dos; Brito, Alexandra; Mello, Fernanda Carvalho de Queiroz; Malaquias, Thiago da Silva Santos; Croda, Julio; Pinhata, Juliana Maira Watanabe; Oliveira, Rosângela Siqueira de; Chimara, Erica; Rossetti, Maria Lúcia; Halon, Maria Laura; Lourenço, Maria Cristina; Medeiros, Reginalda Ferreira de Melo; Montes, Fátima Cristina Onofre Fandinho; Machado, Diana; Viveiros, Miguel; Kritski, Afrânio Lineu
    (1) Background: The Commercial Kit SIRE Nitratase® PlastLabor, is a drug susceptibility test kit used to detect Mycobacterium tuberculosis resistance to first-line TB treatment drugs. The present study aimed at evaluating its performance in a multicenter study. (2) Methods: To determine its accuracy, the proportion methods in Lowenstein Jensen medium or the BACTECTMMGITTM960 system was used as a gold standard. (3) Results: The study revealed that the respective accuracies of the kit with 190 M. tuberculosis clinical isolates, using the proportion methods in Lowenstein Jensen medium or BACTECTMMGITTM960 system as a gold standard, were 93.9% and 94.6%, 96.9% and 94.6%, 98.0% and 97.8%, and 98.0% and 98.9%, for streptomycin, isoniazid, rifampicin, and ethambutol, respectively. (4) Conclusion: Thus, the kit can rapidly screen resistance to streptomycin, isoniazid, rifampicin, and ethambutol. Additionally, it does not require sophisticated equipment; hence, it can be easily used in the laboratories of low and middle income countries.
  • No Thumbnail Available
    Item
    Genotype®MTBDRplus and Xpert®MTB/RIF in the diagnosis of tuberculosis and resistant tuberculosis : cost analysis in a tertiary referral hospital.
    (2020) Soares, Valéria Martins; Almeida, Isabela Neves de; Vater, Maria Cláudia; Alves, Suely; Figueredo, Lida Jouca de Assis; Scherer, Luciene; Kritski, Afranio Lineu; Carvalho, Wânia da Silva; Miranda, Silvana Spindola de
    Introduction: The present study sought to assess the mean and activity based cost (ABC) of the laboratory diagnosis for tuberculosis through the application of conventional and molecular techniques—Xpert®MTB/RIF and Genotype®MTBDRplus—in a tertiary referral hospital in Brazil. Methods: The mean cost and ABC formed the basis for the cost analysis of the TB laboratory diagnosis. Results: The mean cost and ABC were US$ 4.00 and US$ 3.24, respectively, for a bacilloscopy; US$ 6.73 and US$ 5.27 for a Lowenstein-Jensen (LJ) culture; US$ 105.42 and US$ 76.56 for a drug sensitivity test (DST)–proportions method (PM) in LJ; US$ 148.45 and US$ 136.80 for a DST–BACTECTM MGITTM 960 system; US$ 11.53 and US$ 9.89 for an Xpert®MTB/RIF; and US$ 84.21 and US$ 48.38 for a Genotype®MTBDRplus. Conclusions: The mean cost and ABC proved to be good decision-making parameters in the diagnosis of TB and MDR-TB. The effective implementation of algorithms will depend on the conditions at each location.